Rapid Response to the Covid-19 Pandemic
InnoMedica has taken ist responsibility as a pharmaceutical company seriously and reacted quickly to the exceptional circumstances of the Covid-19 pandemic. InnoMedica developed TaliCoVax19 – a biological protein subunit vaccine – based on its nanotechnology platform as a delivery system.
InnoMedica’s TaliCoVax19 vaccine uses SARS-CoV-2 surface proteins produced in a human cell culture system. With the proteins attached to the nanocarrier surface, this design resembles a virus in terms of size and surface area and stimulates to mount a tailored anti-SARS-CoV-2 immune response. As the preclinical studies conducted by InnoMedica demonstrate, immunisation with TaliCoVax19 induces the production of SARS-CoV-2 neutralising antibodies to an extent that is also observed in convalescent Covid-19 patients.
InnoMedica was able to develop a functional vaccine prototype within a few months by carefully optimising the use of available resources. TaliCoVax19 successfully passed the neutralisation test with real coronaviruses at the Institute for Virology and Immunology (IVI) and generated an immune response against Covid-19. In addition, the purely biological structure of the vaccine leads us to expect not only a good immune response but also excellent tolerability.
In April 2020, InnoMedica started initial negotiations with the Federal Office of Public Health (FOPH) during which the vaccination project and the necessary financial expenditures were discussed in detail. With the successful serum neutralisation test, the proof of effectiveness required by the FOPH could be provided. However, after initial positive signals, it became apparent that the political authorities would rather enter into cooperative agreements with large foreign corporations than promote domestic vaccination expertise. In view of the limited liquid funds available and the great potential of Talineuren and Talidox, InnoMedica continues to examine new financing channels and partnerships for a translation project of the vaccination. InnoMedica is in contact with potential buyers and can rapidly manufacture the finished prototype in its own infrastructure and scale it up to large quantities if there is a corresponding demand.
With the development of the vaccine up to proof-of-concept, InnoMedica was able to demonstrate the great potential of the nanotechnology platform in a new field of application, thereby opening up the field of infectious diseases – as a third cornerstone of InnoMedica alongside oncology and neurology – in a very short time.
This highly effective chemotherapy can convince even in late-stage cancers. Talidox substantially improves the benefit/side-effect profile without causing any serious side-effects.
Fostering regeneration instead of merely preventing degeneration – InnoMedica’s novel and innovative therapeutic approach introduces a paradigm shift to neurology. It promises to revolutionize the therapeutic prognosis for patients with Parkinson’s Disease or Amyotrophic Lateral Sclerosis (ALS).